Tumor Outcomes for ROMAN: Phase 3 Trial of Avasopasem Manganese (GC4419) for Severe Oral Mucositis (SOM) in Patients Receiving Chemoradiotherapy (CRT) for Locally Advanced Head and Neck Cancer (LAHNC)-Reference-Cited by-同舟云学术

Tumor Outcomes for ROMAN: Phase 3 Trial of Avasopasem Manganese (GC4419) for Severe Oral Mucositis (SOM) in Patients Receiving Chemoradiotherapy (CRT) for Locally Advanced Head and Neck Cancer (LAHNC)

Published:2022-11 Issue:3 Volume:114 Page:S97-S98
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Anderson C.M.,Lee C.M.,Kelley J.R.,Walker G.V.,Dunlap N.,Bar-Ad V.,Miller D.A.,King V.J.,Peddada A.,Ciuba D.F.,Vincent F.,Muzyka B.C.,Gillespie-Twardy A.L.,Sonis S.,Holmlund J.,Saunders D.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in cancer therapy‐associated oral mucositis;Oral Diseases;2024-07-05

2. What's Changed in 75 Years of RadRes? – An Australian Perspective on Selected Topics;Radiation Research;2024-07-05

3. Comparisons of successful and failed Phase III trials of drugs and biologicals tested for mitigation of oral mucositis in patients being treated with radiotherapy with or without concomitant chemotherapy for cancers of the head and neck;Drug Development Research;2024-04-28

4. Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents;Expert Opinion on Pharmacotherapy;2024-04-12

5. Severe Oral Mucositis: Companies Put Their Money where the Mouth is and Vie for a Marketshare;Onco Zine – The International Oncology Network;2023-09-11